Description
First Name – Kenji Last Name – Hashimoto Institution – Chiba University Center for Forensic Mental Health Department – Division of Clinical Neuroscience City – Chiba 260-8670 State – Chiba Country – Japan Email – hashimoto@faculty.chiba-u.jp Kenji Hashimoto, PhD Chiba University, Chiba, Japan Dr. Hashimoto is a professor and vice-director of Chiba University Center for Forensic Mental Health from 2005. Dr. Hashimoto graduated from Faculty of Pharmaceutical Sciences at Kyushu University, and received PhD. After Dr. Hashimoto worked at Fukuyama University, National Institutes of Health (NIH)/National Institute of Drug Addiction (NIDA)(Baltimore, MD, USA) and Pharmaceutical company, he moved at Chiba University Graduate School of Medicine from 2001. Dr. Hashimoto works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto published more than 550 articles in PubMed listed publications. Dr. Hashimoto focus on the molecular and cellular mechanisms of ketamine’s antidepressant actions. 1) Esketamine (Janssen Pharmaceutical Ltd., USA) Ella J. Daly (edaly2@its.jnj.com) or Jaskaran B. Singh (jsingh25@its.jnj.com) 2) (R)-Ketamine: Kenji Hashimoto (Chiba University, Japan) e-mail: hashimoto@faculty.chiba-u.jp 3) (2R,6R)-HNK (metabolite of R-ketamine): Todd D. Gould (University of Maryland, USA) (gouldlab@me.com) or Panos Zanos (panoszanos1986@gmail.com) 4) Lanicemine and BHV-5000 (low-trapping NMDAR antagonist) Biohaven Pharmaceutical (http://biohavenpharma.com/) 5) Rapastinel and Apimostinel: (Naurex OR Allergan) Joseph R. Moskal (Northwestern University, USA)( j-moskal@northwestern.edu) 6) AV-101 (L-4-chlorokynurenine: NMDAR glycine site antagonist): VistaGen Therapeutics (https://www.vistagen.com/) 7) TAK-653 (AMPAR potentiator): Haruhide Kimura (Takeda Pharmaceutical Co., Ltd, Japan) e-mail: haruhide.kimura@takeda.com 8) mGluR2/3 antagonists: Shigeyuki Chaki (Taisho Pharmaceutical Co, Ltd, Japan) e-mail: s-chaki@taisho.co.jp 9) SAGE-217 PAM at GABA-A: Sage Therapeutics, Inc. USA (https://www.sagerx.com/) 10) NAM at alpha-5 GABA-A: Scott M. Thompson (University of Maryland, USA) e-mail: sthompson@som.umaryland.edu 11) Scopolamine (muscarinic AChR antagonist): Ronald S. Duman (Yale University, USA) e-mail: ronald.duman@yale.edu 12) Sirukumab (IL-6 antibody)(Janssen Pharmaceutical Co, Ltd) Roger S. McIntyre (University of Toronto: roger.mcintyre@uhn.ca) 13) Seltorexant (orexin-2 receptor antagonist): Janssen Pharmaceutical Ltd. (Peter De Boer: pdeboer1@jts.jmj.com) OR Minera Neuroscience Inc. (Remy Luthringer) (http://www.minervaneurosciences.com/) 14) JNJ-55308942 (P2X7 antagonist) Anindya Bhattacharya (J&J, abhatta2@its.jnj.com) 15) Psilocybin (psychedelic drug) Compass Pathway (https://compasspathways.com/)
